impact factor
logo
 

Diagnosis

 

Interleukin-6 and soluble interleukin-6 receptor are elevated in large-vessel vasculitis: a cross-sectional and longitudinal study


1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15

 

  1. Rizzoli Orthopaedic Institute, Bologna, Italy. lia.pulsatelli@ior.it
  2. Arcispedale Santa Maria Nuova-IRCCS, Reggio Emilia, Italy.
  3. Rizzoli Orthopaedic Institute, Bologna, Italy.
  4. Arcispedale Santa Maria Nuova-IRCCS, Reggio Emilia, Italy.
  5. Arcispedale Santa Maria Nuova-IRCCS, Reggio Emilia, Italy.
  6. Rizzoli Orthopaedic Institute, Bologna; and University of Bologna, Italy.
  7. Rizzoli Orthopaedic Institute, Bologna, Italy.
  8. Arcispedale Santa Maria Nuova-IRCCS, Reggio Emilia, Italy.
  9. Arcispedale Santa Maria Nuova-IRCCS, Reggio Emilia, Italy.
  10. Arcispedale Santa Maria Nuova-IRCCS, Reggio Emilia, Italy.
  11. Rizzoli Orthopaedic Institute, Bologna, Italy.
  12. Arcispedale Santa Maria Nuova-IRCCS, Reggio Emilia, Italy.
  13. Arcispedale Santa Maria Nuova-IRCCS, Reggio Emilia, Italy.
  14. Rizzoli Orthopaedic Institute, Bologna; and University of Bologna, Italy.
  15. Arcispedale Santa Maria Nuova-IRCCS, Reggio Emilia, Italy.

CER10105
2017 Vol.35, N°1 ,Suppl.103
PI 0102, PF 0110
Diagnosis

Free to view
(click on article PDF icon to read the article)

PMID: 28466804 [PubMed]

Received: 17/11/2016
Accepted : 13/02/2017
In Press: 20/04/2017
Published: 20/04/2017

Abstract

OBJECTIVES:
To investigate serum levels of IL- 6 and soluble IL-6 receptor (sIL-6R) in patients with large-vessel vasculitis and their relationship with disease activity.
METHODS:
Sera were obtained from 33 Takayasu’s arteritis (TAK) patients and 14 giant cell arteritis (GCA) patients, and from 60 age-matched normal controls (NCs). Disease activity was assessed using 18F-FDG PET/CT and clinical indices including NIH/Kerr criteria and ITAS. Among TAK patients with active disease at baseline, clinical records and serum samples from 11 TAK patients were available for the longitudinal study. IL-6 and sIL-6R serum levels were evaluated using commercial ELISA kits.
RESULTS:
IL-6 and sIL-6R serum levels were significantly higher in both GCA and TAK patients compared to NCs. IL-6 levels in TAK patients were significantly increased irrespective of disease phase, while a significant increase in sIL-6R concentrations was only found in TAK patients with active disease. Conversely, in GCA, IL-6 levels were significantly raised only in patients with active diseases, whereas sIL-6R levels appeared to be significantly higher irrespective of disease activity. Longitudinal analysis showed that levels of sIL-6R in TAK patients were significantly higher only at baseline, compared to NCs, whereas IL-6 levels were found to be significantly increased at each follow-up time point.
CONCLUSIONS:
These overall results might suggest a role for sIL-6R as a potential biomarker for disease activity in TAK patients, whereas in GCA, modifications of IL-6 might better identify patients with active disease.

Rheumatology Article

Rheumatology Addendum